Kane Biotech Unveils Promising Clinical Data at SAWC Fall Conference

Kane Biotech Inc. announced significant clinical findings for its revyve® Antimicrobial Wound Gel during the Symposium on Advanced Wound Care (SAWC) Fall conference, held from September 3-6, 2025, in Las Vegas, Nevada. The presentation, led by Interim Chief Executive Officer Dr. Robert Huizinga, highlighted the efficacy of this innovative gel in treating complex wounds that had persisted for over two years.

The conference gathers a diverse community of wound care professionals, including physicians, nurses, and researchers, to discuss advancements in wound management. Two compelling case studies were presented, showcasing the gel’s impact on patients with severe, non-healing wounds.

Clinical Use of a Novel Thermo-reversible Antimicrobial Wound Gel

In one case study, revyve® was applied to a two-year-old, non-healing Stage 4 sacral ulcer in an elderly patient. Initially, the patient experienced severe pain, rated at 10/10, despite previous treatments with silver-based antimicrobial agents and gelling fiber wound fillers. The introduction of revyve® led to a remarkable change; over a three-week period, pain levels dropped to 0, and significant wound healing was observed, including a reduction in the wound size and a decline in Klebsiella pneumonia cultures.

The second case involved an elderly female patient with a non-healing venous leg ulcer. This full-thickness wound contained slough, eschar, and necrotic tissue. Initially, the patient reported a pain score of 5/10. With the use of revyve® combined with a vibrational debridement tool, pain levels decreased, achieving a score of 0 from week three onward. Healing progressed significantly, with a 60% reduction in wound size over an eight-week treatment period.

Exhibition of Innovative Products

Kane Biotech’s revyve® Antimicrobial Wound Gel and the accompanying Wound Gel Spray, both cleared by the U.S. Food and Drug Administration (FDA), were prominently exhibited at the conference. Dr. Huizinga also engaged with potential distributors in the United States to expand the reach of these innovative wound care solutions.

Kane Biotech is focused on developing advanced treatments that disrupt biofilms, a primary contributor to antibiotic resistance in wounds. The company emphasizes that addressing biofilms is crucial for improving healing outcomes and reducing healthcare costs.

For more information about Kane Biotech and its products, visit the company’s websites at revyvegel.com or kanebiotech.com. Interested parties can also follow the company on social media platforms for updates.

This presentation at SAWC marks a significant step forward for Kane Biotech, demonstrating the potential of revyve® in transforming wound care practices and improving patient outcomes.